Scrambled siRNA GFP Lentivirus

CAT.NOUNITPRICE
LVP015-G2 x 200 μl
$285.00

Specifications


Description

This ready-to-use lentivirus is part of abm’s iLenti™ RNAi Expression System and can be used to knockdown your gene of interest in tranduced target cells. A GFP reporter and puromycin selection marker allow for selection of successfully transduced target cells.

SKULVP015-G
Unit quantity2 x 200 μl
Titer>107 IU/ml
AppearanceLiquid
FormatVirus
SystemLentivirus
Selection MarkerPuromycin
Sequencing PrimersTACGTCCAAGGTCGGGCAGGAAGA
Vector Map

piLenti-siRNA-GFP

Shelf Life1 year when at -80°C
Storage Condition

Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.

FAQs


Do you have the scramble shRNA lentivirus vector for mouse and rat as control?
Our scramble negative control can be used for human, mouse and rat. Please refer to Cat.# LV015-G for ordering information.
Can this vector be used with the 3rd generation packaging system
Yes, our siRNA lentivectors are 3rd generation, but can be packaged using either 2nd or 3rd generation packaging systems.
Could I transiently transfect these vectors to my target cell using lipofectamine or fugene directly? If I can do in this way, how many siRNA do I need to order for one target gene. I notice for each gene you have four options, and also have ***_set. Is one siRNA lentivector enough for knock-down assay?
You can use Lipofectamine to transiently transfect the vectors to your target cells. Since the effect of an siRNA on a gene in a particular cell line can vary, we suggest choosing the set of 4 siRNA constructs to increase your chances of getting good knockdown of your target gene in your cells.
Is the siRNA set composed of lentiviral vectors with shRNAs or siRNAs? Do you validate the RNA interference?
Our RNA interference lentiviral vectors contain siRNAs. We employ a dual convergent promoter system where the sense and antisense strands of the siRNA are expressed by two different promoters rather than in a hairpin loop - to avoid any possible recombination events that can occur. In cases where there are no verified and published siRNA sequences for your gene of interest, we use our siRNA design software to locate suitable target sites. If these designed siRNAs don't give efficient knock down of gene expression in your experiments, we offer a onetime replacement (free of charge) that will contain a new set of sequences to try. ABM guarantees that at least one out of the four siRNA Lentivector constructs purchased in a set will give over 70% knockdown efficiency within appropriate target cells showing >80% transfection efficiency. If these four constructs are still considered to be ineffective, then it is most likely the gene is not susceptible to siRNA knockdown.
Can I use phoenix 293 cells to produce the lentivirus with the lentiviral siRNA plasmids you sell?
The Phoenix 293T cells are suitable for retrovirus packaging but not for lentivirus packaging. To package our lentivectors, you will need to use a 2nd or 3rd generation packaging mix, like the ones we have here: http://www.abmgood.com/Lentivirus-Packaging-Systems.html
I want to transfect the siRNA using Lipofectamine. How much of the siRNA do you recommend to transfect in a 60mm dish for efficient knock down of the gene?
Since every gene is different, it is best to optimize the transfection condition to allow for the most siRNA vector used without having toxicity. Try transfecting a series of 5ug, 8ug, 10ug and 12ug of the siRNA with your cells and the best one will be the highest siRNA used without seeing toxicity.
Are they high copy or low copy plasmids? What is expected plasmid DNA yield?
These are high copy plasmids and should be propagated with an authentic DH5a strain. We typically see a yield of 300-500ug DNA from a 250mL culture.
Is there a provided protocol I can reference when using this product?
You can find the User Manual and Infection Protocol at the following link: http://www.abmgood.com/RNAi-shRNA-siRNA-Expression-Vector.html
What primers can I use to sequence my vectors?
One forward sequencing reaction using the U6 primer should be sufficient: U6 forward sequencing primer 5'-TACGTCCAAGGTCGGGCAGGAAGA-3'
What enzymes can I use to cut the plasmids for verification?
BamHI will cut out GFP in these vectors, so you should see a 0.8kb band when you cut the plasmids with this enzyme (applies only to vectors containing GFP). Another method you can use to check for the insert is to perform an EcoRI digest. The parental vector contains 2 EcoRI sites, one between the two BbsI sites which were used to clone in the insert, and one located immediately after GFP. If the insert is cloned in, the first EcoRI site will be removed, and when this is cut by EcoRI, you will only get a linearized vector band. Ones that are still the parental plasmid with no insert cloned in will still contain both EcoRI sites, and cutting with EcoRI will give 2 bands, ~8.2kb + 0.8kb. Alternatively KpnI should give a 0.9kb band if the insert is present, and a linear vector band only if there is no insert present. The siRNA insert is cloned in with a KpnI site for screening purposes.
Do you stock a non-targeting (control) siRNA lentiviral vector?
We have a scramble siRNA negative control construct (cat#LV015 without GFP, cat#LV015-G with GFP).
How many ug DNA do you recommend to transfect cells in a 6 well plate?
We recommend transfecting 2ug DNA (0.5ug/ul) per well of a 6-well plate
I want to know the shRNA lentivector set contains a mix of 4 plasmids or 4 individual plasmid?
The vector sets are supplied as 4 individual constructs, only the pooled lentivirus is supplied as a mixed solution. Please also note that our system utilizes the expression of mature siRNA sequences from two convergent promoters and this is not a hairpin loop, shRNA based system.
Can you please advice on a protocol for vector extraction from filter paper?
1) Cut out the circle on the filter paper (this is where the DNA will be spotted), and then cut it into tiny pieces into a 1.5ml tube. 2) Put 30-50ul of PCR-grade water, 10mM Tris, or TE buffer to elute the DNA from the filter paper. The liquid may be completely soaked up by the filter, this is OK. Cap the tube and leave at room temperature for 5 minutes. 3) Centrifuge the tube at high speed for 1 minute to collect the liquid, or use a pipette and "compress" the filter paper at the bottom of the tube to squeeze out as much liquid as possible. Collect the liquid in a new tube, and then use DH5a competent cells to amplify the plasmid, use the suitable antibiotic to select for positive clones.
Is the 5'LTR wildtype? For the 3' LTR, is the U3 region deleted?
This is not the wildtype 5'LTR. The U3 region is removed.
How does lentiviral delivery of siRNA differ from shRNA?
siRNA and shRNA have the same intention and they are to silent gene expression by cleaving the target mRNA. However, their differences are as follows: a) siRNA (small interfering RNA) is a linear sequence that binds to the target mRNA and cleaves it, preventing the unwanted protein from being made b) shRNA (short hairpin RNA) is a DNA construct encoding a sequence of single stranded RNA and its complement, separated by a stuffer fragment, allowing the RNA molecule to fold back on itself, creating a hairpin loop Traditionally, siRNA is made synthetically and introduced into the cells as is which is short lived; whereas shRNA is cloned into a vector and then introduced cell's genome, which can prolong expression. However, shRNA poses a difficulty on amplification and sequencing and thus it is not easy to construct. abm has come up with a novel technology where we combined the ability to clone siRNA into a vector, but with the same effect as shRNA. With the help of a dual convergent promoter vector system, the sense and antisense strands of the siRNA are expressed by two different promoters rather than in a hairpin loop, which thus avoids any possible recombination events that can occur. However, the siRNA sequence is expressed in both directions, and therefore mimicks the actions of shRNA.
References


17
  • Koo, JW et al. "Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area" Nat. Neurosci. 8(3):415-422 (2015). DOI: 10.1038/nn.3932. PubMed: 25643298.
  • Korb, E et al. "BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice" Nat Neurosci 18(10):1464-1473 (2015). DOI: 10.1038/nn.4095. PubMed: 26301327.
  • Ramachandra, C et al. "ErbB4 Activated p38γ MAPK Isoform Mediates Early Cardiogenesis Through NKx2.5 in Human Pluripotent Stem Cells" Stem Cells 34.2:288 (2016). DOI: 10.1002/stem.2223. Application: RNA Interference.
  • Shimizu, T et al. "Microglia-Induced Activation of Noncanonical Wnt Signaling Aggravates Neurodegeneration in Demyelinating Disorders" Mol. Cell. Biol. 36.21:2728-2741 (2016). DOI: 10.1128/MCB.00139-16. Application: Research.
  • Wang, et al. "Interleukin 6 induces expression of NADPH oxidase 2 in human aortic endothelial cells via long noncoding RNA MALAT1" Die Pharmazie - An International Journal of Pharmaceutical Sciences 71.10:592 (2016). DOI: 10.1691/ph.2016.6598. Application: Transduce HAOECs.
  • Ji, Y., Li, L., Ma, Y.-X., Li, W.-T., Li, L., Zhu, H.-Z., … Zhou, J.-R. "Quercetin inhibits growth of hepatocellular carcinoma by apoptosis induction in part via autophagy stimulation in mice" The Journal of Nutritional Biochemistry 69:108–119 (2019). DOI: 10.1016/j.jnutbio.2019.03.018.
  • Li, W. Y., Zhang, W. T., Cheng, Y. X., Liu, Y. C., Zhai, F. G., Sun, P., ... & Wang, Y. "Inhibition of KLF7-targeting microRNA 146b promotes sciatic nerve regeneration"  Neuroscience bulletin  34(3):419-437 (2018).
  • Liang, Y., Song, X., Li, Y., Su, P., Han, D., Ma, T., … Yang, Q. "circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer" Oncogene 38(42):6850–6866 (2019). DOI: 10.1038/s41388-019-0926-z.
  • Verma, M., Asakura, Y., & Asakura, A. "Inhibition of microRNA‐92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy–related phenotype in mdx mice" Muscle & Nerve 59(5):594–602 (2019). DOI: 10.1002/mus.26433.
  • Wei, X., Li, X., Yan, W., Zhang, X., Sun, Y., & Zhang, F. "SKP2 promotes hepatocellular carcinoma progression through nuclear AMPK-SKP2-CARM1 signaling transcriptionally regulating nutrient-deprived autophagy induction"  Cellular Physiology and Biochemistry  47(6):2484-2497 (2018).
  • Wu., Chien-Wei., . "Downregulation of MiR-144 by Triptolide Enhanced p85α−PTEN Complex Formation Causing S Phase Arrest of Human Nasopharyngeal Carcinoma Cells" European Journal of Pharmacology 855:137-148 (2019). DOI: 10.1016/j.ejphar.2019.04.052..
  • Wu, M.-J., Chen, Y.-S., Kim, M. R., Chang, C.-C., Gampala, S., Zhang, Y., … Chang, C.-J. "Epithelial-Mesenchymal Transition Directs Stem Cell Polarity via Regulation of Mitofusin" Cell Metabolism 29(4):993–1002.e6 (2019). DOI: 10.1016/j.cmet.2018.11.004.
  • Xiang, X., Zhou, Y., Sun, H., Tan, S., Lu, Z., Huang, L., & Wang, W. "Ivabradine abrogates TNF-α-induced degradation of articular cartilage matrix" International Immunopharmacology 66:347–353 (2019). DOI: 10.1016/j.intimp.2018.11.035.
  • Yu, S., Ren, H., Li, Y., Liang, X., Ning, Q., Chen, X., ... & Hu, T. "HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin-Resistance in Lung Adenocarcinoma Cells"  Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)  18(14):2062-2067 (2018).
  • Zhang, M., Wang, B., Urabe, G., Huang, Y., Plutzky, J., Kent, K. C., & Guo, L.-W. "The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation" Cellular Signalling 61:20–29 (2019). DOI: 10.1016/j.cellsig.2019.05.005.
  • Zhou, Y., Lei, J., Xie, Q., Wu, L., Jin, S., Guo, B., ... & Zhang, J. "Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5" Science Advances 5(11):eaax0629 (2019).
  • Zhu, R., Xue, X., Shen, M., Tsai, Y., Keng, P. C., Chen, Y., … Chen, Y. "NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer" Experimental Cell Research 374(1):181–188 (2019). DOI: 10.1016/j.yexcr.2018.11.022.